Whole transcriptome analysis of schinifoline treatment in Caenorhabditis elegans infected with Candida albicans.

• Natural plant schinifoline has a certain inhibitory effect on the treatment of Candida albicans in C. elegans. • The results showed that the pathogenicity of C. albicans to C. elegans was caused by abnormal protein function. • Schinifoline regulates lysosomal pathway related genes that accelerate the metabolism and degradation of abnormal proteins. Candida albicans is an opportunistic fungal human pathogen that has been causing an increasing number of deaths each year. Due to the widespread use of broad-spectrum antibiotics and immunosuppressants, C. albicans resistance to these therapies has increased. Thus, natural plant inhibitors are being investigated for treating C. albicans infections. Schinifoline is a 4-quinolinone alkaloid with antibacterial, insecticidal, antitumor, and other biological activities. Here, we explored the effects of schinifoline on C. albicans in C. elegans and extracted RNA from uninfected C. elegans , C. elegans infected with C. albicans , and C. elegans infected with C. albicans and treated with 100 mg/l schinifoline. Our results showed that there were significant differences among the three groups. The GO and KEGG pathway analysis suggested that the pathogenicity of C. albicans to C. elegans was caused by abnormal protein function. Schinifoline regulates lysosomal pathway related genes that accelerate the metabolism and degradation of abnormal proteins, thereby inhibiting the negative effects of C. albicans in vivo. These findings advance our understanding of the molecular mechanisms underlying schinifoline inhibition of C. albicans. [ABSTRACT FROM AUTHOR]